Mahmood Razavi (Orange, USA) speaks to Venous News about the recently initiated VIVID trial – a prospective, multicentre, single-arm study which has just begun enrolment and is designed to evaluate the safety and efficacy of the Vesper DUO Venous Stent System in the treatment of patients with iliofemoral occlusive disease.
Razavi states that the Vesper DUO Venous Stent System is a unique portfolio with both the DUO–HYBRID and DUO–EXTEND stents with varying mechanical properties. The DUO–HYBRID stent is designed to provide crush resistance where it is needed, as well as flexibility and radial force where necessary along with the modular stent arrangement– ultimately helping to eliminate the “common practice that is currently used where we mix and match stents” and allowing for the use of just one type of stent to treat the entire iliofemoral segment as needed.
Razavi goes on to outline the VIVID trial, which has just started enrolment. Commenting on what is different about the VIVID study design, Razavi notes that there is a prespecified requirement for enrolment of three deep venous disease categories (nonthrombotic iliac vein lesion [NIVL], acute thrombotic and chronic post thrombotic).
This video is sponsored by Vesper Medical.